Based on an ATP competitive inhibitor as FAK ligand, alternative CRBN- and VHL-recruiting FAK degraders were disclosed by Boehringer Ingelheim.117 Degrader BI-0319 (66) (Fig. 24b), the best degrader of the VHL-series, as well as the best CRBN-recruiting PROTAC qualified as potent FAK degraders in 12 liver and lung cancer cell lines and exhibited markedly improved kinase selectivity. The gene discussed is PTK2; the disease is lung cancer.